MedTrace Logo

Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H

NCT00458250 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2008-11-18

No results posted yet for this study

Summary

Many patients suffering various malignant and non-malignant diseases need hematopoietic stem cell transplantation from a healthy person. In the majority of cases there is no matched related or unrelated donor.

Some researchers have been performed transplantation from semi-matched (haploidentical) related donors with relatively good results.

Chinese researchers have been performed this kind of transplantation using CAMPATH-1H and their reports indicates good results.

Chinese populations have more homogenous genetic background than Iranians. In this project, we are going to study the feasibility of this method of haploidentical transplantation in Iranian patients.

Conditions

  • Leukemia, Myeloid, Acute
  • Leukemia, Lymphoblastic, Acute

Interventions

PROCEDURE

Haploidentical hematopoietic stem cell transplantation

DRUG

Busulfan

DRUG

Cyclophosphamide

DRUG

CAMPATH-1H

DRUG

Cyclosporin A

DRUG

Methotrexate

Sponsors & Collaborators

  • Tehran University of Medical Sciences

    lead OTHER

Principal Investigators

  • Mohammadreza Ostadali, MD, Ph.D. · Hematology-Oncology & BMT Research Center

  • Ardeshir Ghavamzadeh, MD · Hematology-Oncology & BMT Research Center

  • Kamran Alimoghaddam, MD · Hematology-Oncology & BMT Research Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
2 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2008-02-29

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00458250 on ClinicalTrials.gov